NCNA
NuCana Plc
NASDAQ · Healthcare · Biotechnology · GB
$1.32
−0.75%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$1.34
From 52W high−81.20%
Volume10490.00
Market cap$5.49M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$1.34
From 52W high
−81.20%
Volume
10490.00
Market cap
$5.49M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
1.0x
P/E (TTM)
—
RSI (14)
45.4
MomentumView details →
1D Return
−0.75%
YTD Return
−62.50%
SummaryUpdated Jun 1, 2026
NuCana plc (NASDAQ:NCNA) is a clinical-stage biopharmaceutical company founded in 1997 and headquartered in Edinburgh, United Kingdom. The company went public in September 2017, transitioning from its former name NuCana BioMed Limited. NuCana focuses on developing innovative cancer treatments using its proprietary ProTide technology platform, with multiple drug candidates currently progressing through various phases of clinical trials for treating solid tumors and blood cancers.
Similar companies
Latest newsMore news →
No recent news for NCNA.